Robust PEMGARDA Performance and Pipeline Progress Underscore Invivyd Buy Rating and $10 Price Target

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Invivyd. The associated price target remains the same with $10.00.

Patrick Trucchio has given his Buy rating due to a combination of factors related to Invivyd’s current performance and future prospects. He highlights that preliminary fourth-quarter and full-year 2025 revenues from PEMGARDA surpassed both his estimates and market expectations, while the company’s strengthened cash position provides ample funding for late-stage trials and commercialization efforts. In his view, this financial foundation, paired with visible revenue growth, supports a favorable risk‑reward profile at current valuation levels.

Trucchio also places significant emphasis on the advancement of VYD2311, particularly the Phase 3 DECLARATION trial and the Fast Track designation from the FDA, viewing these as key value drivers ahead of mid‑2026 data. He considers the shift from infusion-based delivery to intramuscular, pharmacy-delivered administration as an important catalyst that could broaden uptake beyond highly immunocompromised patients. Additionally, he notes that the emerging RSV and measles programs, while not yet fully captured in his near-term valuation, enhance the strategic value of the INVYMAB platform and support long-term growth, which collectively underpins his $10 price target and Buy recommendation.

Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IVVD in relation to earlier this year.